Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Purpose: Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC). Mcl-1 inhibitors, such as the BH3-mimetic EU-5346, therefore represent an exciting new class of targeting agents and are a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Breast cancer research and treatment
Year: 2018, Volume: 173, Issue: 3, Pages: 585-596 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-018-5022-5 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/s10549-018-5022-5
|
| Author Notes: | Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T. Opferman, Michael H. Cardone, Dirk Jäger, Klaus Podar |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1669010244 | ||
| 003 | DE-627 | ||
| 005 | 20230428192156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190711r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-018-5022-5 |2 doi | |
| 035 | |a (DE-627)1669010244 | ||
| 035 | |a (DE-599)KXP1669010244 | ||
| 035 | |a (OCoLC)1341233473 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vallet, Sonia |d 1976- |e VerfasserIn |0 (DE-588)105867207X |0 (DE-627)797396403 |0 (DE-576)414826493 |4 aut | |
| 245 | 1 | 0 | |a Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer |c Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T. Opferman, Michael H. Cardone, Dirk Jäger, Klaus Podar |
| 264 | 1 | |c 2019 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First Online: 29 October 2018 | ||
| 500 | |a Gesehen am 11.07.2019 | ||
| 520 | |a Purpose: Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC). Mcl-1 inhibitors, such as the BH3-mimetic EU-5346, therefore represent an exciting new class of targeting agents and are a current focus of widespread cancer-drug development efforts.Methods: ONCOMINE analysis was utilized to compare expression profiles of Bcl-2 family members across all major BC subgroups. Potential toxicities of EU-5346 were evaluated using iPS-generated cardiomyocytes, blood cells and astrocytes. The anti-BC cell activity of EU-5346-based therapies was evaluated using [3H]-thymidine uptake and spheroid-forming assays as well as immunoblotting and the Chou-Talalay method. Protein level-based activity of EU-5346, the specific anti-Bcl-2 inhibitor ABT-199 and the specific anti-Bcl-xL inhibitor WEHI-539 was verified in Mcl-1Δ/null versus Mcl-1wt/wt MEFs. Results: We previously demonstrated significant anti-tumor activity of EU-5346 in all BC subtypes. Our present results go further and suggest that EU-5346 may induce limited adverse events such as cardiotoxicity, hematotoxicity, and neurotoxicity, frequently observed with other BH3 mimetics. As demonstrated by our mathematical scoring model, the prediction of EU-5643-induced IC50 not only relies on the protein level of Mcl-1 but also on Bak, Bim, and Noxa. Synergistic anti-BC activity of low-dose EU-5346 with the BH3 mimetics ABT-199 or WEHI-539 was observed only in those BC cells expressing Bcl-2 or Bcl-xL, respectively. Similarly, when combined with tamoxifen or trastuzumab, low-dose EU-5346 induced significant anti-BC activity in hormone receptor positive or Her2-positive BC cells, respectively. Finally, EU-5346 in combination with paclitaxel induced synergistic anti-BC activity in both paclitaxel-sensitive and paclitaxel-resistant TNBC cells. Conclusion: These data strongly support the further clinical development of EU-5346 to improve BC patient survival. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a BH3 mimetics | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Combination therapies | |
| 650 | 4 | |a Mathematical scoring model | |
| 650 | 4 | |a Mcl-1 | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Podar, Klaus |e VerfasserIn |0 (DE-588)1058672169 |0 (DE-627)797396594 |0 (DE-576)414826795 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 173(2019), 3, Seite 585-596 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnas |a Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer |
| 773 | 1 | 8 | |g volume:173 |g year:2019 |g number:3 |g pages:585-596 |g extent:12 |a Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-018-5022-5 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-018-5022-5 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190711 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1058672169 |a Podar, Klaus |m 1058672169:Podar, Klaus |d 50000 |e 50000PP1058672169 |k 0/50000/ |p 11 |y j | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 10 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 6 | ||
| 998 | |g 105867207X |a Vallet, Sonia |m 105867207X:Vallet, Sonia |d 50000 |e 50000PV105867207X |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1669010244 |e 3492662692 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer","title_sort":"Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer"}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"language":["eng"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1981 -"],"origin":[{"dateIssuedKey":"1981","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1981-","publisher":"Springer Science + Business Media B.V. ; Kluwer"}],"language":["eng"],"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"title":[{"title_sort":"Breast cancer research and treatment","title":"Breast cancer research and treatment"}],"disp":"Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancerBreast cancer research and treatment","part":{"volume":"173","text":"173(2019), 3, Seite 585-596","extent":"12","issue":"3","pages":"585-596","year":"2019"},"recId":"320433722","id":{"zdb":["2004077-5"],"issn":["1573-7217"],"eki":["320433722"]},"type":{"media":"Online-Ressource","bibl":"periodical"}}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Vallet, Sonia","given":"Sonia","family":"Vallet"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Andreas","family":"Schneeweiss","display":"Schneeweiss, Andreas"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Jäger, Dirk","family":"Jäger","given":"Dirk"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Podar","given":"Klaus","display":"Podar, Klaus"}],"name":{"displayForm":["Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T. Opferman, Michael H. Cardone, Dirk Jäger, Klaus Podar"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1669010244","note":["First Online: 29 October 2018","Gesehen am 11.07.2019"],"physDesc":[{"extent":"12 S."}],"id":{"eki":["1669010244"],"doi":["10.1007/s10549-018-5022-5"]}} | ||
| SRT | |a VALLETSONIRATIONALLY2019 | ||